A ge-related macular degeneration (AMD) remains the leading cause of visual loss in adults older than 65 years. Retinal angiomatous proliferation (RAP) is a newly recognized manifestation of exudative AMD that has a poor natural history and demonstrated resistance to treatment with conventional laser photocoagulation. A novel surgical technique has been developed in this pilot series that shows promise in the treatment of this subtype of neovascular lesions. Through specific surgical lysis of the feeding arteriole and draining venule of an RAP lesion, improvement in visual acuity has been noted. This has been correlated with resolution of intraretinal edema and flattening of associated pigment epithelial detachment, which was confirmed by fluorescein angiography, optical coherence tomography, and high-speed indocyanine green angiography.
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Arch Ophthalmol. 2003; 121:558-561 Retinal angiomatous proliferation (RAP) has recently been described in a subset of patients with exudative age-related macular degeneration (AMD). 1 In RAP, the neovascular process originates from the retinal vasculature as opposed to the underlying choriocapillaris, as is seen with typical choroidal neovascularization. On clinical examination, the presence of intraretinal or preretinal hemorrhages associated with retinal vessels that abruptly curve toward the choroid is consistent with RAP. Cystoid macular edema, lipid exudates, and pigment epithelial detachment (PED) may be present.
A classification system has been reported to further subdivide these lesions. Briefly, RAP stage 1 involves the proliferation of abnormal vessels in the intraretinal space, akin to the intraretinal microvascular abnormalities seen in diabetes mellitus. This intraretinal neovascularization often demonstrates retinal-retinal anastomoses and may continue to proliferate and leak. Stage 2 is defined by the presence of intraretinal edema and may be associated with serous PED and/or subretinal neovascularization. In stage 3, retinochoroidal anastomoses are present; associated fibrovascular PED is a late finding and is also seen in RAP stage 3. On fluorescein angiography, RAP appears as purely occult or minimally classic choroidal neovascularization. Standard indocyanine green (ICG) angiography reveals a hot spot in late frames. High-speed ICG angiography allows an accurate identification of the RAP lesion, retinal feeding arterioles, draining venules, and associated retinalretinal or retinochoroidal anastomoses. 1 Unfortunately, patients with RAP have poor visual outcomes after treatment with conventional laser photocoagulation. [2] [3] [4] Affected individuals often demonstrate a subacute decrease in visual acuity over the course of several months. Because of the inefficacy of laser photocoagulation and the poor natural history of RAP, alternative treatment options warrant further investigation. Patients with RAP stage 1 may be asymptomatic and remain undetected. Patients with RAP stage 3 often already have a disciform scar with irreversible overlying photoreceptor dysfunction. For these reasons, attention is focused on RAP stage 2. In a small series of patients, we describe a new surgical technique for the ablation of these angiomatous lesions. (Figure 1) , ICG angiography, optical coherence tomography, and high-speed ICG video angiography (Figure 2 ). Patients were included in the study if they had exudative AMD with RAP stage 2 and associated serous PED, as determined by clinical and diagnostic examination. Snellen visual acuities were obtained preoperatively, 4 to 6 weeks postoperatively, and at least 6 months after surgical intervention.
Patients underwent surgical ablation of RAP retinal feeder vessels at the Wills Eye Hospital, Philadelphia, Pa, and were followed up during a 6-month period. The RAP lesions and their corresponding retinal feeder arterioles and draining venules were identified on still frames from the high-speed ICG angiogram. A tracing was made to serve as a guide for surgical lysis. Lower-order vessels were chosen for ablation to avoid significant inner retinal ischemia. After a standard 3-port pars plana vitrectomy was performed, the posterior hyaloid face was detached and trimmed to the far periphery under wide-field viewing. The high-speed ICG angiogram tracing was used to identify the specific retinal feeder vessels targeted for excision. A partial thickness retinotomy with a 22-gauge needle was made superficial to the vessels; this retinotomy was placed at least 0.5 disc diameters away from the fovea. The RAP feeder vessels were then incised with intraocular vertical scissors (Synergetics, St Charles, Mo), with the arteriole lysed prior to the venule (Figure 3) . The infusion pressure was elevated temporarily to ensure hemostasis, and endodiathermy was applied to prevent recanalization.
RESULTS
Patient data are summarized in the Table. The mean age of the patients was 82 years. All patients were female and had a history of hypertension controlled with medication. Preoperatively, the mean initial Snellen visual acuity was 20/ 200 as determined by conversion to the logarithm of the minimal angle of resolution. Postoperatively, the mean final visual acuity improved to 20/70 at a follow-up interval of 6 to 12 months. Macular thickening resolved in all eyes that underwent RAP ablation (Figure 4) , with collapse of associated PED. No eyes developed surgical complications, such as endophthalmitis or retinal detachment, in the postoperative period.
COMMENT
Retinal angiomatous proliferation is a distinct clinical entity in the spectrum of patients with exudative AMD. The presence of an RAP lesion is suggested by preretinal or intraretinal hemorrhage at the point where the macular edema is thickest with or without associated PED. To date, there are no effective treatments for the subset of AMD patients with RAP. We present a novel surgical approach that may benefit patients with this manifestation.
Because RAP lesions, by definition, originate from the retinal vasculature, the focus has been on surgical lysis of the retinal feeding arterioles and draining venules associated with angiomatous proliferation. Patients with RAP stage 2 appear to be the best candidates for this procedure. In this small series of patients who underwent surgical ablation of an RAP lesion, improvement in clinical, angiographic, and tomographic appearance was noted in all cases. Upon successful lysis of the feeding and draining vessels, complete resolution of retinal fluid and PED was generally noted within 7 to 10 days. This translates into a trend toward corresponding improvement in visual acuity. In the current series, the lesions remained closed without recurrence of the RAP.
One theoretical advantage of this surgical approach is that it spares the retinal pigment epithelium (RPE), unlike laser photocoagulation. The reduction of macular thickening with preservation of the underlying RPE may allow for better functioning of the overlying outer We acknowledge that the lack of a control group, relatively short follow-up period, and small number of patients are inherent flaws of this study. Nonetheless, surgical lysis of RAP stage 2 lesions appears to be a promising approach to a condition that currently has a poor natural history and no effective treatment. No complications were encountered in this small-group study. A large controlled, prospective trial is needed to ultimately determine the efficacy and safety of surgical RAP ablation. 
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